| Literature DB >> 35121965 |
Kathryn L Simpson1, Ruth Stoney1,2, Kristopher K Frese1, Nicole Simms1, William Rowe1,3, Simon P Pearce1, Sam Humphrey1, Laura Booth1, Derrick Morgan1, Marek Dynowski4, Francesca Trapani1, Alessia Catozzi1, Mitchell Revill1, Thomas Helps1, Melanie Galvin1, Luc Girard5, Daisuke Nonaka6, Louise Carter6,7, Matthew G Krebs6,7, Natalie Cook6,7, Mathew Carter1, Lynsey Priest1, Alastair Kerr1, Adi F Gazdar5, Fiona Blackhall6,7,8, Caroline Dive9,10.
Abstract
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription factor (NETF) expression. Circulating-tumor-cell-derived explant models (CDX) recapitulate donor patients' tumor morphology, diagnostic NE marker expression and chemotherapy responses. We describe a biobank of 38 CDX models, including six CDX pairs generated pretreatment and at disease progression revealing complex intra- and intertumoral heterogeneity. Transcriptomic analysis confirmed three of four previously described subtypes based on ASCL1, NEUROD1 and POU2F3 expression and identified a previously unreported subtype based on another NETF, ATOH1. We document evolution during disease progression exemplified by altered MYC and NOTCH gene expression, increased 'variant' cell morphology, and metastasis without strong evidence of epithelial to mesenchymal transition. This CDX biobank provides a research resource to facilitate SCLC personalized medicine.Entities:
Mesh:
Year: 2020 PMID: 35121965 DOI: 10.1038/s43018-020-0046-2
Source DB: PubMed Journal: Nat Cancer ISSN: 2662-1347